Pliant Therapeutics (PLRX)
Pliant Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.6M
Short interest
settlement 2026-10-15
10.4
Days to cover
-1.0 days vs prior
37.8%
Short share of volume
2026-11-02
1,382
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PLRX is 4,634,593 shares, up 942,177 shares over the last month. Over the last 48 readings it ranged from 2,582,648 shares (30 June 2026) to 7,538,612 shares (15 January 2025). At the reported average volume of 447K shares a day that is 10.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/plrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,634,593 | +9.1% | 447,369 | 10.36 |
| 2026-09-30 | 4,246,484 | +15.0% | 372,372 | 11.40 |
| 2026-09-15 | 3,692,416 | +12.6% | 416,117 | 8.87 |
| 2026-08-31 | 3,278,573 | +18.4% | 456,271 | 7.19 |
| 2026-08-14 | 2,768,737 | -1.4% | 361,784 | 7.65 |
| 2026-07-31 | 2,806,615 | -0.5% | 490,096 | 5.73 |
| 2026-07-15 | 2,821,841 | +9.3% | 862,175 | 3.27 |
| 2026-06-30 | 2,582,648 | -8.3% | 367,554 | 7.03 |
| 2026-06-15 | 2,816,654 | -18.0% | 537,720 | 5.24 |
| 2026-05-29 | 3,436,210 | -0.3% | 568,852 | 6.04 |
| 2026-05-15 | 3,444,679 | +0.4% | 329,821 | 10.44 |
| 2026-04-30 | 3,431,231 | -5.8% | 644,125 | 5.33 |
| 2026-04-15 | 3,640,410 | -9.6% | 348,757 | 10.44 |
| 2026-03-31 | 4,025,957 | +6.0% | 562,083 | 7.16 |
| 2026-03-13 | 3,799,636 | +0.4% | 483,114 | 7.86 |
| 2026-02-27 | 3,785,164 | -8.9% | 777,424 | 4.87 |
| 2026-02-13 | 4,156,054 | -0.6% | 797,845 | 5.21 |
| 2026-01-30 | 4,181,177 | +11.5% | 975,741 | 4.29 |
| 2026-01-15 | 3,750,180 | +21.0% | 1,077,903 | 3.48 |
| 2025-12-31 | 3,100,213 | -2.6% | 790,115 | 3.92 |
| 2025-12-15 | 3,182,879 | -20.3% | 2,720,571 | 1.17 |
| 2025-11-28 | 3,993,673 | +3.7% | 871,395 | 4.58 |
| 2025-11-14 | 3,851,283 | +3.4% | 703,421 | 5.48 |
| 2025-10-31 | 3,723,100 | -2.7% | 1,107,800 | 3.36 |
| 2025-10-15 | 3,827,992 | +2.1% | 772,912 | 4.95 |
| 2025-09-30 | 3,749,724 | +0.3% | 371,342 | 10.10 |
| 2025-09-15 | 3,737,575 | +11.3% | 786,169 | 4.75 |
| 2025-08-29 | 3,357,945 | +1.2% | 693,068 | 4.85 |
| 2025-08-15 | 3,318,100 | +1.3% | 1,278,975 | 2.59 |
| 2025-07-31 | 3,276,920 | +13.9% | 1,120,150 | 2.93 |
| 2025-07-15 | 2,877,684 | +5.3% | 1,226,089 | 2.35 |
| 2025-06-30 | 2,734,036 | -18.7% | 2,201,674 | 1.24 |
| 2025-06-13 | 3,364,746 | -14.2% | 897,811 | 3.75 |
| 2025-05-30 | 3,921,167 | -22.2% | 1,324,047 | 2.96 |
| 2025-05-15 | 5,038,014 | -2.1% | 684,528 | 7.36 |
| 2025-04-30 | 5,147,283 | +1.1% | 668,456 | 7.70 |
| 2025-04-15 | 5,089,401 | +15.4% | 1,342,902 | 3.79 |
| 2025-03-31 | 4,408,424 | +10.8% | 2,021,292 | 2.18 |
| 2025-03-14 | 3,978,061 | +21.0% | 4,624,974 | 1.00 |
| 2025-02-28 | 3,288,803 | -7.0% | 2,613,166 | 1.26 |
| 2025-02-14 | 3,535,747 | -51.1% | 5,517,644 | 1.00 |
| 2025-01-31 | 7,234,821 | -4.0% | 571,263 | 12.66 |
| 2025-01-15 | 7,538,612 | +5.2% | 376,712 | 20.01 |
| 2024-12-31 | 7,167,979 | -0.8% | 693,300 | 10.34 |
| 2024-12-13 | 7,223,567 | -0.3% | 479,458 | 15.07 |
| 2024-11-29 | 7,242,084 | -0.7% | 557,099 | 13.00 |
| 2024-11-15 | 7,291,853 | +1.1% | 454,723 | 16.04 |
| 2024-10-31 | 7,215,830 | +3.8% | 384,692 | 18.76 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PLRX volume is 37.8%, down 4.4 points over the last five sessions. Over the last 30 readings it ranged from 9.0% (28 September 2026) to 70.6% (13 October 2026). The latest reading is 2.2 points below the 30-session average of 39.9%, on 151K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 57K | 151K | 37.8% | 0 |
| 2026-10-30 | 35K | 76K | 46.7% | 123 |
| 2026-10-29 | 47K | 97K | 48.8% | 0 |
| 2026-10-28 | 12K | 66K | 18.9% | 0 |
| 2026-10-27 | 20K | 151K | 13.5% | 0 |
| 2026-10-26 | 62K | 146K | 42.1% | 0 |
| 2026-10-23 | 95K | 189K | 50.1% | 0 |
| 2026-10-22 | 82K | 140K | 58.6% | 0 |
| 2026-10-21 | 67K | 203K | 33.2% | 0 |
| 2026-10-20 | 64K | 151K | 42.2% | 0 |
| 2026-10-19 | 47K | 114K | 41.2% | 60 |
| 2026-10-16 | 119K | 385K | 30.9% | 0 |
| 2026-10-15 | 148K | 313K | 47.2% | 0 |
| 2026-10-14 | 344K | 618K | 55.8% | 50 |
| 2026-10-13 | 107K | 151K | 70.6% | 0 |
| 2026-10-12 | 24K | 136K | 18.0% | 0 |
| 2026-10-09 | 60K | 134K | 45.1% | 0 |
| 2026-10-08 | 150K | 334K | 45.0% | 0 |
| 2026-10-07 | 197K | 425K | 46.3% | 0 |
| 2026-10-06 | 66K | 139K | 47.3% | 0 |
| 2026-10-05 | 85K | 143K | 59.6% | 0 |
| 2026-10-02 | 67K | 222K | 30.2% | 780 |
| 2026-10-01 | 105K | 175K | 60.0% | 0 |
| 2026-09-30 | 56K | 107K | 52.1% | 0 |
| 2026-09-29 | 38K | 91K | 41.7% | 0 |
| 2026-09-28 | 15K | 165K | 9.0% | 0 |
| 2026-09-25 | 53K | 189K | 28.0% | 0 |
| 2026-09-24 | 34K | 100K | 34.4% | 4 |
| 2026-09-23 | 33K | 105K | 31.7% | 0 |
| 2026-09-22 | 23K | 186K | 12.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in PLRX is 1,382 shares, up 1,309 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 August 2026) to 69,303 shares (20 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 1,382 | $1.00 | $1K |
| 2026-09-10 | 73 | $1.15 | $84 |
| 2026-09-09 | 74 | $1.14 | $84 |
| 2026-08-26 | 4,110 | $1.19 | $5K |
| 2026-08-21 | 6,923 | $1.12 | $8K |
| 2026-08-20 | 69,303 | $1.17 | $81K |
| 2026-08-13 | 4 | $1.07 | $4 |
| 2026-08-11 | 1 | $1.04 | $1 |
| 2026-08-10 | 1,668 | $1.05 | $2K |
| 2026-08-04 | 523 | $1.04 | $544 |
| 2026-08-03 | 232 | $1.04 | $241 |
| 2026-07-29 | 8 | $1.07 | $9 |
| 2026-07-01 | 355 | $1.14 | $405 |
| 2026-06-30 | 4,311 | $1.15 | $5K |
| 2026-06-11 | 1,922 | $1.16 | $2K |
| 2026-06-10 | 1,072 | $1.19 | $1K |
| 2026-05-13 | 4,525 | $1.18 | $5K |
| 2026-05-08 | 6,197 | $1.24 | $8K |
| 2026-05-07 | 285 | $1.23 | $351 |
| 2026-04-09 | 2,363 | $1.36 | $3K |
| 2026-03-26 | 1,000 | $1.31 | $1K |
| 2026-03-24 | 3,998 | $1.29 | $5K |
| 2025-12-22 | 19 | $1.23 | $23 |
| 2025-11-28 | 1,402 | $1.58 | $2K |
| 2025-11-24 | 1,176 | $1.55 | $2K |
| 2025-11-21 | 1,385 | $1.56 | $2K |
| 2025-11-14 | 3 | $1.72 | $5 |
| 2025-10-22 | 1,282 | $1.87 | $2K |
| 2025-10-17 | 10,201 | $1.65 | $17K |
| 2025-10-14 | 12,875 | $1.49 | $19K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for PLRX in the last 90 days. The most recent filings are listed below. Latest filing: Kuo Minnie (Chief Operating Officer) on 2026-01-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-01-20 | Kuo Minnie | Chief Operating Officer | Sell | 7K | $1.28 | $9K | 38K |
| 2026-01-20 | Cummings Keith Lamont | Chief Financial Officer | Sell | 24K | $1.28 | $31K | 297K |
| 2026-01-20 | Coulie Bernard | President and CEO | Sell | 89K | $1.28 | $114K | 506K |
| 2026-01-20 | Cheung Lily | Chief Human Resource Officer | Sell | 8K | $1.28 | $10K | 45K |
| 2025-01-23 | Coulie Bernard | President and CEO | Grant | 163K | $0.00 | $0 | 593K |
| 2025-01-23 | Cummings Keith Lamont | Chief Financial Officer | Grant | 57K | $0.00 | $0 | 319K |
| 2025-01-23 | Lefebvre Eric | Chief Medical Officer | Grant | 46K | $0.00 | $0 | 240K |
| 2025-01-23 | Hull Hans | Chief Business Officer | Grant | 40K | $0.00 | $0 | 252K |
| 2025-01-23 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 35K | $0.00 | $0 | 106K |
| 2025-01-23 | Cheung Lily | Chief Human Resource Officer | Grant | 26K | $0.00 | $0 | 50K |
| 2025-01-22 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 10K | $10.99 | $112K | 71K |
| 2025-01-17 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 13K | $11.20 | $149K | 81K |
| 2025-01-17 | Cheung Lily | Chief Human Resource Officer | Sell | 4K | $11.20 | $42K | 25K |
| 2025-01-17 | Lefebvre Eric | Chief Medical Officer | Sell | 18K | $11.20 | $207K | 195K |
| 2025-01-17 | Hull Hans | Chief Business Officer | Sell | 16K | $11.20 | $178K | 212K |
| 2025-01-17 | Cummings Keith Lamont | Chief Financial Officer | Sell | 20K | $11.20 | $226K | 263K |
| 2025-01-17 | Coulie Bernard | President and CEO | Sell | 52K | $11.20 | $587K | 431K |
| 2024-07-10 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 8K | $11.56 | $89K | 94K |
| 2024-07-10 | Coulie Bernard | President and CEO | Sell | 39K | $11.56 | $447K | 483K |
| 2024-07-10 | Cummings Keith Lamont | Chief Financial Officer | Sell | 11K | $11.56 | $126K | 282K |
| 2024-07-10 | Hull Hans | Chief Business Officer | Sell | 10K | $11.56 | $114K | 227K |
| 2024-07-10 | Lefebvre Eric | Chief Medical Officer | Sell | 12K | $11.56 | $142K | 213K |
| 2024-07-09 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 15K | $0.00 | $0 | 102K |
| 2024-07-09 | Coulie Bernard | President and CEO | Grant | 76K | $0.00 | $0 | 522K |
| 2024-07-09 | Cummings Keith Lamont | Chief Financial Officer | Grant | 21K | $0.00 | $0 | 293K |
| 2024-07-09 | Hull Hans | Chief Business Officer | Grant | 19K | $0.00 | $0 | 237K |
| 2024-07-09 | Lefebvre Eric | Chief Medical Officer | Grant | 24K | $0.00 | $0 | 225K |
| 2024-05-02 | Cummings Keith Lamont | Chief Financial Officer | Exercise or conversion | 21K | $2.08 | $44K | 272K |
| 2024-01-23 | Coulie Bernard | President and CEO | Grant | 128K | $0.00 | $0 | 445K |
| 2024-01-23 | Cheung Lily | Chief Human Resource Officer | Grant | 26K | $0.00 | $0 | 27K |
| 2024-01-23 | Cummings Keith Lamont | Chief Financial Officer | Grant | 55K | $0.00 | $0 | 250K |
| 2024-01-23 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 32K | $0.00 | $0 | 87K |
| 2024-01-23 | Hull Hans | Chief Business Officer | Grant | 32K | $0.00 | $0 | 217K |
| 2024-01-23 | Lefebvre Eric | Chief Medical Officer | Grant | 43K | $0.00 | $0 | 200K |
| 2024-01-17 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 5K | $17.23 | $90K | 55K |
| 2024-01-17 | Lefebvre Eric | Chief Medical Officer | Sell | 10K | $17.23 | $177K | 157K |
| 2024-01-17 | Coulie Bernard | President and CEO | Sell | 26K | $17.23 | $443K | 316K |
| 2024-01-17 | Hull Hans | Chief Business Officer | Sell | 10K | $17.23 | $169K | 185K |
| 2024-01-17 | Cummings Keith Lamont | Chief Financial Officer | Sell | 10K | $17.23 | $169K | 195K |
| 2023-08-04 | Hull Hans | Chief Business Officer | Exercise or conversion | 9K | $2.08 | $18K | 215K |
| 2023-08-04 | Hull Hans | Chief Business Officer | Sell | 20K | $20.01 | $401K | 195K |
| 2023-08-03 | Hull Hans | Chief Business Officer | Sell | 2K | $20.00 | $36K | 206K |
| 2023-08-03 | Hull Hans | Chief Business Officer | Sell | 13K | $20.00 | $261K | 206K |
| 2023-08-03 | Hull Hans | Chief Business Officer | Exercise or conversion | 2K | $2.08 | $4K | 208K |
| 2023-07-20 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 5K | $17.55 | $83K | 60K |
| 2023-07-17 | Coulie Bernard | President and CEO | Sell | 70K | $18.01 | $1.3M | 342K |
| 2023-07-17 | Cummings Keith Lamont | Chief Financial Officer | Sell | 20K | $18.01 | $356K | 204K |
| 2023-07-17 | Hull Hans | Chief Business Officer | Sell | 18K | $18.01 | $323K | 219K |
| 2023-07-17 | Lefebvre Eric | Chief Medical Officer | Sell | 22K | $18.01 | $402K | 167K |
| 2023-07-17 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 13K | $18.01 | $230K | 65K |
| 2023-07-14 | Coulie Bernard | President and CEO | Grant | 138K | $0.00 | $0 | 412K |
| 2023-07-14 | Cummings Keith Lamont | Chief Financial Officer | Grant | 39K | $0.00 | $0 | 224K |
| 2023-07-14 | Hull Hans | Chief Business Officer | Grant | 35K | $0.00 | $0 | 237K |
| 2023-07-14 | Lefebvre Eric | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 190K |
| 2023-07-14 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 27K | $0.00 | $0 | 78K |
| 2023-06-13 | Cummings Keith Lamont | Chief Financial Officer | Exercise or conversion | 31K | $2.08 | $64K | 185K |
| 2023-06-09 | Cummings Keith Lamont | Chief Financial Officer | Exercise or conversion | 6K | $2.08 | $12K | 154K |
| 2023-04-03 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 200 | $27.46 | $5K | 51K |
| 2023-04-03 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 3K | $26.74 | $72K | 51K |
| 2023-03-30 | Coulie Bernard | President and CEO | Sell | 35K | $26.52 | $937K | 275K |
| 2023-03-30 | Cummings Keith Lamont | Chief Financial Officer | Sell | 10K | $26.52 | $264K | 148K |
| 2023-03-30 | Hull Hans | Chief Business Officer | Sell | 9K | $26.52 | $240K | 202K |
| 2023-03-30 | Lefebvre Eric | Chief Medical Officer | Sell | 11K | $26.52 | $298K | 146K |
| 2023-03-30 | Ouimette Mike | General Counsel & Corp. Sec'y | Sell | 5K | $26.52 | $129K | 54K |
| 2023-03-29 | Coulie Bernard | President and CEO | Grant | 69K | $0.00 | $0 | 310K |
| 2023-03-29 | Cummings Keith Lamont | Chief Financial Officer | Grant | 19K | $0.00 | $0 | 158K |
| 2023-03-29 | Hull Hans | Chief Business Officer | Grant | 18K | $0.00 | $0 | 211K |
| 2023-03-29 | Lefebvre Eric | Chief Medical Officer | Grant | 22K | $0.00 | $0 | 157K |
| 2023-03-29 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 14K | $0.00 | $0 | 59K |
| 2023-02-03 | Coulie Bernard | President and CEO | Sell | 10K | $33.36 | $325K | 245K |
| 2023-02-03 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $6.22 | $93K | 255K |
| 2023-02-03 | Coulie Bernard | President and CEO | Sell | 5K | $34.08 | $179K | 240K |
| 2023-02-02 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $6.22 | $93K | 255K |
| 2023-02-02 | Coulie Bernard | President and CEO | Sell | 13K | $34.13 | $457K | 242K |
| 2023-02-02 | Coulie Bernard | President and CEO | Sell | 2K | $34.96 | $56K | 240K |
| 2023-02-01 | Coulie Bernard | President and CEO | Sell | 105 | $35.55 | $4K | 240K |
| 2023-02-01 | Coulie Bernard | President and CEO | Sell | 5K | $34.78 | $189K | 240K |
| 2023-02-01 | Coulie Bernard | President and CEO | Sell | 9K | $34.15 | $323K | 246K |
| 2023-02-01 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $6.22 | $93K | 255K |
| 2023-01-31 | Coulie Bernard | President and CEO | Exercise or conversion | 4K | $6.22 | $28K | 255K |
| 2023-01-31 | Coulie Bernard | President and CEO | Sell | 15K | $34.92 | $524K | 240K |
| 2023-01-31 | Coulie Bernard | President and CEO | Exercise or conversion | 11K | $2.08 | $22K | 251K |
| 2023-01-30 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $2.08 | $31K | 255K |
| 2023-01-30 | Coulie Bernard | President and CEO | Sell | 11K | $33.98 | $387K | 244K |
| 2023-01-30 | Coulie Bernard | President and CEO | Sell | 4K | $34.66 | $125K | 240K |
| 2023-01-27 | Coulie Bernard | President and CEO | Sell | 10K | $35.09 | $343K | 410K |
| 2023-01-27 | Coulie Bernard | President and CEO | Sell | 221 | $36.64 | $8K | 409K |
| 2023-01-27 | Coulie Bernard | President and CEO | Sell | 6K | $36.06 | $227K | 240K |
| 2023-01-27 | Coulie Bernard | President and CEO | Sell | 9K | $35.42 | $308K | 246K |
| 2023-01-27 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $2.08 | $31K | 255K |
| 2023-01-26 | Coulie Bernard | President and CEO | Sell | 15K | $35.09 | $526K | 419K |
| 2023-01-26 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $2.08 | $31K | 255K |
| 2023-01-26 | Coulie Bernard | President and CEO | Sell | 15K | $35.29 | $529K | 240K |
| 2023-01-25 | Coulie Bernard | President and CEO | Exercise or conversion | 15K | $2.08 | $31K | 109K |
| 2023-01-25 | Coulie Bernard | President and CEO | Sell | 2K | $33.29 | $56K | 94K |
| 2023-01-25 | Coulie Bernard | President and CEO | Sell | 13K | $32.40 | $431K | 96K |
| 2023-01-25 | Coulie Bernard | President and CEO | Grant | 146K | $0.00 | $0 | 240K |
| 2023-01-25 | Lefebvre Eric | Chief Medical Officer | Grant | 57K | $0.00 | $0 | 134K |
| 2023-01-25 | Ouimette Mike | General Counsel & Corp. Sec'y | Grant | 39K | $0.00 | $0 | 45K |
| 2023-01-25 | Hull Hans | Chief Business Officer | Grant | 54K | $0.00 | $0 | 192K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of PLRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is ADAR1 Capital Management, LLC at 8.9% of the class (5,509,724 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G | ADAR1 Capital Management, LLCinvestment adviser, other entity | 5.5M | 8.9% | 2026-06-30 |
| 2026-08-14 | 13G | Daniel Schneebergerparent holding company, individual | 5.5M | 8.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 2.1M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 1.4M | 2.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 1.4M | 2.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 1.4M | 2.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 725K | 1.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 725K | 1.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 673K | 1.1% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 47K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Steven A. Cohenindividual | 47K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 47K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Woodline Partners LPinvestment adviser, partnership | 2.0M | 3.3% | 2025-12-31 |
| 2026-01-08 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 545K | 0.9% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 3 | Deep Track Capital, LPinvestment adviser, other entity | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | Deep Track Biotechnology Master Fund, Ltd.corporation | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | David Kroinparent holding company, individual | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding PLRX at their latest 13F. JSON5 of the 30 tracked managers held PLRX at their latest 13F, $8.0M in total at quarter-end prices. Two Sigma Investments is the largest at $2.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 2.3M | $2.6M | 0.00% | +10K |
| Citadel Advisors | 2026-06-30 | 2.1M | $2.4M | 0.00% | -1.1M |
| Renaissance Technologies | 2026-06-30 | 2.0M | $2.3M | 0.00% | +197K |
| Millennium Management | 2026-06-30 | 559K | $638K | 0.00% | -621K |
| Point72 Asset Management | 2026-06-30 | 20K | $23K | 0.00% | -27K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Pliant Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Pliant Therapeutics (PLRX), SEC CIK 1746473, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-01-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 1746473Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of PLRX is sold short?
4,634,593 shares were held short at the 2026-10-15 settlement, 10.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PLRX's daily short volume?
On 2026-11-02, 57,090 of the 151,241 PLRX shares reported to FINRA were sold short, 37.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PLRX have fails to deliver?
The SEC's latest file shows 1,382 PLRX shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are PLRX insiders buying or selling?
No open-market insider trades were reported for PLRX in the last 90 days. The most recent filings are listed below. Latest filing: Kuo Minnie (Chief Operating Officer) on 2026-01-20.
Who owns 5% or more of PLRX?
2 holders report 5% or more of PLRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is ADAR1 Capital Management, LLC at 8.9% of the class (5,509,724 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own PLRX?
5 of the 30 tracked 13F managers held PLRX shares at their latest filing, $8.0M in all. The largest: Two Sigma Investments (2.3M shares, $2.6M), Ken Griffin's Citadel Advisors (2.1M shares, $2.4M), Renaissance Technologies (2.0M shares, $2.3M), Izzy Englander's Millennium Management (559K shares, $638K), Steve Cohen's Point72 Asset Management (20K shares, $23K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.